



ORIGINAL ARTICLE / ОРИГИНАЛНИ РАД

Gastroesophageal reflux disease and functional dyspepsia – what is the real burden on health-related quality of life

Tamara Babić¹, Igor Dragičević², Aleksandar Ćorac³, Goran Trajković^{4,5}, Luka Nikolić⁶, Miloš Bjelović^{1,5}

¹Clinical Center of Serbia, University Clinic for Digestive Surgery, First Clinical Surgical Hospital, Department for Minimally Invasive Upper Digestive Surgery, Belgrade, Serbia;

²Public Health Institute, Šabac, Serbia;

³University of Priština, Faculty of Medicine, Kosovska Mitrovica, Serbia;

⁴University of Belgrade, Faculty of Medicine, Institute for Medical Statistics, Belgrade, Serbia;

⁵University of Belgrade, Faculty of Medicine, Belgrade, Serbia;

⁶University of Edinburgh, Edinburgh Medical School: Biomedical Sciences, College of Medicine and Veterinary Medicine, Edinburgh, United Kingdom

SUMMARY

Introduction/Objective Recently published studies have addressed the significant impairment of health-related quality of life (HRQoL) in patients suffering from gastroesophageal reflux disease (GERD) and functional dyspepsia (FD). To the best of our knowledge, none of the previously published studies have compared the impact of GERD and FD on HRQoL.

The aim of the study was to determine the impact of GERD and FD on HRQoL.

Methods The current sample was extrapolated from a large cross-sectional population-based study conducted in primary health care facilities. Primary care physicians and general internists diagnosed GERD according to the Montreal definition for population-based studies. Also, primary care physicians and general internists diagnosed FD based on the Rome III criteria. The Serbian version of the generic self-administered Center for Disease Control and Prevention questionnaire was used. We used the propensity score method to match GERD and FD samples on variables such as age, gender, education, and adherence to therapy.

Results Regarding self-rated health, similar results were obtained from both groups. The Center for Disease Control and Prevention HRQoL questionnaire version 4 further revealed that functional dyspepsia led to greater disturbances of every-day functioning in regard to the criteria of physically healthy, mentally healthy, and activity limitation days.

Conclusion The results of the study have shown significant impairment of HRQoL in both groups, but, surprisingly, patients with FD experienced more limitations to their every-day functioning compared to patients with GERD.

Keywords: quality of life; gastroesophageal reflux; functional dyspepsia; population study; surveys and questionnaires

INTRODUCTION

It has been estimated that gastroesophageal reflux disease (GERD) and functional dyspepsia (FD) represent the most common gastrointestinal diseases in the general population, with a rising prevalence worldwide [1, 2]. While heartburn is a cardinal symptom of GERD, there is consensus that abdominal discomfort or pain centered in the upper abdomen, as well as the absence of any organic esophageal lesions, is the primary symptom of FD. Abdominal pain or discomfort is often associated with bloating, nausea, heartburn, vomiting, etc. [3]. Although not life-threatening, patients with GERD or FD perceive the effects of their condition to a similar degree to patients with other serious chronic diseases [4, 5].

Recently published studies have addressed the significant impairment of health-related

quality of life (HRQoL) in patients suffering from GERD in the areas of eating and drinking, physical activity, psychological wellbeing, as well as reduced vitality and poor sleep [6–10]. Furthermore, studies have shown that the direct costs of GERD range between PPP\$172 (purchasing power parity in US dollars) and PPP\$176 per person per year, thus causing a substantial economic burden [11, 12]. On the other hand, FD has been shown to significantly reduce HRQoL in the domains of general health, vitality, and the emotional and mental health of the patients compared to the general population [13, 14]. A study analyzing patient-reported costs and claims in the USA found that FD patients incurred additional expenses of more than US\$2,000/year [15].

Although previously published studies have addressed the significant impairment in HRQoL domains in patients suffering from

Received • Примљено:

April 10, 2017

Revised • Ревизија:

December 10, 2017

Accepted • Прихваћено:

December 12, 2017

Online first: December 22, 2017

Correspondence to:

Tamara BABIĆ
University Clinic for Digestive Surgery
Clinical Center of Serbia
6 Dr Koste Todorovića Street
Belgrade 11000, Serbia
b.tamara86@gmail.com

GERD and FD separately, to the best of our knowledge none of them have compared the impact of GERD and FD on HRQoL.

The aim of this study was to distinguish which of these two diseases has a greater impact on HRQoL of affected patients.

METHODS

The current sample was extrapolated from a large cross-sectional population-based study conducted in primary healthcare facilities in urban and rural areas of Serbia, regarding HRQoL of patients suffering from chronic non-transmittable diseases. The inclusion criteria were as follows: patients of both genders, aged 18–90 years, willing and able to participate in this study and complete the questionnaire.

GERD was diagnosed by primary care physicians and general internists according to the Montreal definition of GERD for population-based studies, which included patients with mild symptoms of heartburn and/or regurgitation occurring at least two days per week, or moderate/severe symptoms of heartburn and/or regurgitation occurring at least one day per week [16]. FD was also diagnosed by primary care physicians and general internists based on the Rome III criteria for FD, and encompassed patients with at least one of the following symptoms: postprandial fullness, early satiety, epigastric burning, and epigastric pain; occurring for the last three months with the onset of symptoms at least six months prior to participating in the study [17]. The FD group included both patients with postprandial distress syndrome and those with epigastric pain syndrome. Classification of GERD and FD was performed according to the International Classification of Diseases, Tenth Revision (ICD-10). Exclusion criteria included other significant upper gastrointestinal disorders and complications of GERD, as well as other chronic non-transmittable diseases, which are known to greatly impair HRQoL (diabetes mellitus, angina pectoris, depression, chronic obstructive pulmonary disease, etc.) [18]. Inclusion and exclusion criteria ensured that only patients with GERD and FD were eligible for study participation.

The current study was approved by the local ethics committee. Written informed consent was obtained from all participants prior to study participation.

In the current study, the Serbian version of the generic self-administered Center for Disease Control and Prevention questionnaire (CDC-HRQOL-4) was used. The questionnaire is divided into three sets of questions regarding general well-being, usual activities limitations including work and leisure activities, and disease symptoms [19]. The participants of the study completed the questionnaire in the office of their PCPs. Previously published surveys had demonstrated that results from the CDC-HRQOL-4 questionnaire had good test/retest reliability and strong internal validity [19, 20]. In this respect, the questionnaire has an advantage over other HRQoL instruments with more difficult methodology and limited practical value [21].

Statistical analysis

We used the propensity score method to match GERD and FD samples on variables such as age, gender, education, and adherence to therapy. The PSMATCH 2 Stata module was used for propensity scoring with one-to-one nearest neighbor matching on the following covariates: age, gender, education, and therapy administration [22]. The PSMATCH 2 Stata technique was first published by Rosenbaum and Rubin [23] and represents a matched sampling method used to remove bias due to potential confounding factors. This matching technique is used mainly for analyzing causal effects in intervention studies; however, it is also used in typical observational studies, including those with a cross-sectional design.

The descriptive statistics, including the mean and standard deviation of numerical data, as well as the numerical values and percentages of categorical variables, were used to characterize the study sample. The Pearson χ^2 test was used to compare categorical variables between the GERD and FD populations, and the independent samples t-test and the Mann–Whitney U-test were used for the numerical variables. The level of significance was set at $\alpha = 0.05$. The statistical analysis was performed using IBM SPSS Statistics, Version 20.0 (IBM Corp., Armonk, NY, USA).

RESULTS

The response for this survey was over 90%. The 2,472 participants suitable for analysis were divided into two groups based on the inclusion and exclusion criteria (1,236 diagnosed with GERD and 1,236 diagnosed with FD). All included participants were Caucasian. The sociodemographic characteristics of the participants are summarized in Table 1. The study included 593 (48%) males, 643 (52%) females in the GERD group, 599 (48.5%) males, and 637 (51.5%) females in the FD group. The mean age in the GERD group was 50.8 years in the GERD group and 50.5 years in the FD group. There was no statistically significant difference regarding gender, age, level of education and therapy administration between the two groups. The

Table 1. Sociodemographic characteristics of patients in the gastroesophageal reflux disease (GERD) group and the functional dyspepsia (FD) group

Characteristics	GERD (n = 1,236)	FD (n = 1,236)	p
Gender, n (%)			
Male	593 (48.0)	599 (48.5)	0.809
Female	643 (52.0)	637 (51.5)	
Age (years), mean \pm SD	50.8 \pm 14.1	50.5 \pm 14.3	0.670
Education, n (%)			
Lower education level	175 (14.2)	181 (14.6)	0.982
Higher education level	1,061 (85.8)	1,055 (85.4)	
Therapy administration, n (%)			
No	29 (2.3)	34 (2.8)	0.803
Yes, OTC medication	96 (7.8)	98 (7.9)	
Yes, administered by PCP	1,111 (89.9)	1,104 (89.3)	

OTC – over the counter; PCP – primary care physician

education level of the participants was classified based on the International Standard Classification of Education into lower education level, which included participants with no education or primary education only; and higher education level, which included participants with secondary education, tertiary, and post-tertiary education.

Self-rated health and number of unhealthy days are shown in Table 2. Regarding current health status, 547 (44.7%) patients in the GERD group self-rated their health as fair or poor, compared to 510 (41.8%) patients in the FD group ($p > 0.05$). The mean number of mentally unhealthy days was 5.4 ± 7.4 days in the GERD group, vs. 6.3 ± 7.5 days in the FD group ($p < 0.01$). The mean number of activity limitation days was 4.4 ± 6.9 in the GERD group, compared to 5.3 ± 7.3 days in the FD group ($p = 0.001$).

There was no statistically significant difference between the two groups regarding the participants' self-rated health in the previous 30 days. In other criteria, however, there was a statistically significant difference observed between the two groups, all in favor of FD. The differences were specifically in the criteria regarding unhealthy days in the previous 30 days, physically unhealthy days in the previous 30 days, mentally unhealthy days in the previous 30 days, and activity limitation days in the previous 30 days.

In the GERD group, the mean number of days with poor sleep during the previous 30 days was 7.2 ± 7.6 compared to 8.4 ± 7.7 in the FD group ($p < 0.001$). Regarding physical pain, 114 (9.2%) patients had ≥ 14 pain limitation days, compared to 128 (10.4%) patients in the FD group.

On further analyzing the occurrence of symptoms in the previous 30 days, a statistically significant difference was observed regarding days with poor sleep, once again in favor of FD, as showed in Table 3.

DISCUSSION

GERD and FD represent the most prevalent conditions in patients seeking a medical consultation for abdominal symptoms [24]. Traditionally, medical practitioners are focused on objective clinical findings and their treatment, while patients are mostly concerned with their symptoms. This difference is particularly important in cases of non-erosive reflux disease and FD, the distinguishing features of which are the absence of objective endoscopic findings. Thus, measuring HRQoL provides additional information beyond what could be obtained by standard clinical examination.

Indeed, studies have demonstrated that both GERD and FD carry a significant burden regarding impaired HRQoL in the domains of general health, mental and emotional well-being, as well as lower work productivity [25]. Unfortunately, none of these studies have compared the diseases regarding their effect on HRQoL, nor had they determined which disease patients on average deemed more troublesome.

To the best of our knowledge, this is the first study of this type worldwide. The validation of this study was achieved using adequate study methodology and reliable

Table 2. Self-rated health of patients in the gastroesophageal reflux disease (GERD) group and the functional dyspepsia (FD) group

Characteristics	GERD	FD	p
Self-rated health, n (%)			
Excellent, very good, good	677 (55.3%)	709 (58.2%)	0.155
Fair, poor	547 (44.7%)	510 (41.8%)	
Number of unhealthy days, (mean \pm SD)			
Unhealthy days	10.7 ± 10.6	11.9 ± 10.5	0.005
Physically unhealthy days	6.7 ± 7.5	7.3 ± 7.2	0.005
Mentally unhealthy days	5.4 ± 7.4	6.3 ± 7.5	< 0.001
Activity limitation days	4.4 ± 6.9	5.3 ± 7.3	0.001
Patients with ≥ 14 unhealthy days, n (%)			
Unhealthy days	314 (25.4%)	374 (30.3%)	0.007
Physically unhealthy days	194 (15.7%)	192 (15.5%)	0.912
Mentally unhealthy days	151 (12.2%)	158 (12.8%)	0.670
Activity limitation days	125 (10.1%)	139 (11.2%)	0.362

Table 3. Duration of symptoms in patients in the gastroesophageal reflux disease (GERD) group and the functional dyspepsia (FD) group during the previous 30 days

Symptoms	GERD	FD	p
Duration of symptoms, (mean \pm SD)			
Pain limitation days	5.1 ± 6.4	5.4 ± 6.5	0.159
Days with depression	6.1 ± 7.8	5.8 ± 7.2	0.919
Days with anxiety	7.0 ± 7.6	7.3 ± 7.7	0.463
Days with poor sleep	7.2 ± 7.6	8.4 ± 7.7	< 0.001
Days with good health	12.4 ± 10.0	11.9 ± 9.5	0.375
Patients with ≥ 14 unhealthy days, n (%)			
Pain limitation days	114 (9.2%)	128 (10.4%)	0.343
Days with depression	137 (11.1%)	114 (9.2%)	0.126
Days with anxiety	150 (12.1%)	172 (13.9%)	0.189
Days with poor sleep	160 (12.9%)	209 (16.9%)	0.006
Days with good health	351 (28.4%)	350 (28.2%)	0.964

self-administered generic CDC-HRQOL-4 questionnaire. The questions, despite their brevity, captured the key concepts of health as defined by the World Health Organization back in 1948, "A state of complete physical, mental, and social well-being – not merely the absence of disease or infirmity" [26]. Today, there are many validated disease-specific instruments for GERD and FD. However, disease-specific instruments do not allow for comparisons with illnesses other than GERD and FD, nor with healthy individuals in the general population. Therefore, generic HRQoL measures are valuable in supplementing disease-specific instruments and enabling a comparison between two different diseases.

Over 90% of participants who were asked to participate in this study completed the questionnaire. This is a representative sample of those affected by GERD and FD in the general population in Serbia. The previous studies reported the prevalence of overlap of GERD with FD around 7.5–8.4%, especially in the cases of non-erosive reflux disease [27]. Unrecognized syndrome overlap was thought to be an important factor in partial or complete proton pump inhibitor failure in GERD therapy. While the Rome II classification of functional gastrointestinal disorders classified syndromes by their prominent symptoms, it failed to identify sub-groups with a homogenous

underlying pathophysiological mechanism [28]. After further pathophysiological studies, the Rome III criteria were developed to identify and distinguish between different syndromes within the functional gastrointestinal disorders group, especially FD [29]. To minimize the chance of syndrome overlapping, both GERD and FD were classified according to the current Montreal and Rome III protocols. Furthermore, statistical analysis showed no statistically significant difference between either of the groups regarding the use of self-administered over-the-counter medication and medication prescribed by primary care physicians, hence excluding the proton pump inhibitor failures as potentially unrecognized FD patients.

In our study, there was no statistically significant difference between the two groups regarding sociodemographic characteristics. All the domains comprising the CDC-HRQOL-4 questionnaire were significantly impaired in both groups, with unhealthy days, physically unhealthy days, mentally unhealthy days, and activity limitation days as the areas of most marked disturbance. These results are consistent with previously published results [6, 13]. The “unhealthy days” variable has continuous, cardinal, and bounded (range = 0 to 30 days) mathematical properties and represents the briefest validated set of generic HRQoL measures, with minimal overlap with the “physically” and “mentally unhealthy days” variables in comparison with other instruments, hence the reliably describing HRQoL oscillations over a period of time. Regarding self-rated health, similar results were obtained from both groups [30].

The CDC-HRQOL-4 questionnaire further revealed that FD led to greater disturbances of every-day functioning in regard to the criteria of physically healthy, mentally

healthy, and activity limitation days [6, 13]. Patients with FD experienced more days with poor sleep compared to the GERD group. Sleep disorders are quite common medical problems, and have been associated with several diseases, including GERD and FD [10].

CONCLUSION

The results of the study have shown significant impairment of HRQoL in both groups, but, surprisingly, patients with FD experienced more limitations to their every-day functioning in the areas of HRQoL compared to patients with GERD. Thus, while often underestimated and considered a minor public health problem compared to other chronic diseases, FD confers a significant burden to patients' HRQoL. We believe that the results of this study offer insight into the complex relationship between GERD, FD, and HRQoL impairment. A better understanding of these mechanisms may allow for better disease management in the future.

This study has several limitations. Firstly, the results reflected the status of the predominantly Caucasian population of a single country (Serbia). Another possible limitation is that the generic HRQoL instruments used to measure health domains tend to be more physical or mobility-based. Although the CDC-HRQoL-4 questionnaire allowed for the comparison of two different diseases regarding their effect on HRQoL, unfortunately we were unable to determine which symptoms patients with GERD and FD deemed most troublesome. We hope that this will be investigated in further studies.

REFERENCES

1. Tominaga K, Fujikawa Y, Tanaka F, Tanigawa T, Shiba M, Watanabe T, et al. [Rome III classification and characteristics of Japanese patients with functional dyspepsia]. *Nihon Shokakibyō Gakkai Zasshi*. 2014; 111(6):1079–87.
2. Fujiwara Y, Arakawa T. Overlap in patients with dyspepsia/functional dyspepsia. *J Neurogastroenterol Motil*. 2014; 20(4):447–57.
3. Oshima T, Miwa H. [Gastrointestinal motility disorders of functional dyspepsia]. *Nihon Shokakibyō Gakkai Zasshi*. 2014; 111(6):1071–8.
4. Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. *Am J Med*. 1998; 104(3):252–8.
5. Talley NJ, Locke GR, Saito YA, Almazar AE, Bouras EP, Howden CW, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. *Gastroenterology*. 2015; 149(2):340–9.e2.
6. Mody R, Bolge SC, Kannan H, Fass R. Effects of gastroesophageal reflux disease on sleep and outcomes. *Clin Gastroenterol Hepatol*. 2009; 7(9):953–9.
7. Camilleri M, Bueno L, de Ponti F, Fioramonti J, Lydiard RB, Tack J. Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders. *Gastroenterology*. 2006; 130(5):1421–34.
8. Dubois RW, Aguilar D, Fass R, Orr WC, Elfant AB, Dean BB, et al. Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity. *Aliment Pharmacol Ther*. 2007; 25(4):487–500.
9. Dibaise JK, Islam RS, Dueck AC, Roarke MC, Crowell MD. Psychological distress in Rome III functional dyspepsia patients presenting for testing of gastric emptying. *Neurogastroenterol Motil*. 2016; 28(2):196–205.
10. Bjelović M, Babić T, Dragičević I, Ćorac A, Trajković G. The burden of gastroesophageal reflux disease on patients' daily lives: a cross-sectional study conducted in a primary care setting in Serbia. *Srp Arh Celok Lek*. 2015; 143(11–12):676–80.
11. Brook RA, Wahlqvist P, Kleinman NL, Wallander MA, Campbell SM, Smeeding JE. Cost of gastro-oesophageal reflux disease to the employer: a perspective from the United States. *Aliment Pharmacol Ther*. 2007; 26(6):889–98.
12. Moghimi-Dehkordi B, Vahedi M, Khoshkrood Mansoori B, Kasaean A, Safaee A, Habibi M, et al. Economic burden of gastro-oesophageal reflux disease and dyspepsia: A community-based study. *Arab J Gastroenterol*. 2011; 12(2):86–9.
13. Choi MG, Jung HK. Health related quality of life in functional gastrointestinal disorders in Asia. *J Neurogastroenterol Motil*. 2011; 17(3):245–51.
14. Bjelović M, Zarić N, Babić T, Dragičević I, Ćorac A, Trajković G. Health-related quality of life in patients with functional dyspepsia. *Vojnosanit Pregl*. 2017; 74(11):1025–9.
15. Lacy BE, Weiser KT, Kennedy AT, Crowell MD, Talley NJ. Functional dyspepsia: the economic impact to patients. *Aliment Pharmacol Ther*. 2013; 38(2):170–7.
16. Vakili N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus G. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol*. 2006; 101(8):1900–20.
17. Shih DQ, Kwan LY. All roads lead to Rome: update on Rome III Criteria and new treatment options. *Gastroenterol Rep*. 2007; 1(2):56–65.
18. Malfertheiner P, Hallerback B. Clinical manifestations and complications of gastroesophageal reflux disease (GERD). *Int J Clin Pract*. 2005; 59(3):346–55.
19. Andresen EM, Catlin TK, Wyrwich KW, Jackson-Thompson J. Retest reliability of surveillance questions on health related quality of life. *J Epidemiol Community Health*. 2003; 57(5):339–43.

20. Dominick KL, Ahern FM, Gold CH, Heller DA. Relationship of health-related quality of life to health care utilization and mortality among older adults. *Aging Clin Exp Res*. 2002; 14(6):499–508.
21. Frank L, Kleinman L, Rentz A, Ciesla G, Kim JJ, Zacker C. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. *Clin Ther*. 2002; 24(4):675–89.
22. Caliendo M, Kopeinig S. Some practical guidance for the implementation of propensity score matching. *Journal of Economic Surveys*. 2008; 22(1):31–72.
23. Rosenbaum H, Rubin D. The central role of the propensity score in observational studies for causal effects. *Biometrika*. 1983; 70:41–55.
24. Oshima T, Miwa H. Epidemiology of Functional Gastrointestinal Disorders in Japan and in the World. *J Neurogastroenterol Motil*. 2015; 21(3):320–9.
25. Wahlqvist P, Carlsson J, Stalhammar NO, Wiklund I. Validity of a Work Productivity and Activity Impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD)—results from a cross-sectional study. *Value Health*. 2002; 5(2):106–13.
26. Huber M, Knottnerus JA, Green L, van der Horst H, Jadad AR, Kromhout D, et al. How should we define health? *BMJ*. 2011; 343:d4163.
27. Locke GR 3rd, Zinsmeister AR, Fett SL, Melton LJ 3rd, Talley NJ. Overlap of gastrointestinal symptom complexes in a US community. *Neurogastroenterol Motil*. 2005; 17(1):29–34.
28. Karamanolis G, Caenepeel P, Arts J, Tack J. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. *Gastroenterology*. 2006; 130(2):296–303.
29. Tack J, Caenepeel P, Arts J, Lee KJ, Sifrim D, Janssens J. Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. *Gut*. 2005; 54(10):1370–6.
30. Moriarty DG, Zack MM, Kobau R. The Centers for Disease Control and Prevention's Healthy Days Measures – population tracking of perceived physical and mental health over time. *Health Qual Life Outcomes*. 2003; 1:37.

Гастроезофагеална рефлуксна болест и функционална диспепсија – који је њихов утицај на квалитет живота повезан са здрављем

Тамара Бабич¹, Игор Драгичевић², Александар Ћорац³, Горан Трајковић^{4,5}, Лука Николић⁶, Милош Бјеловић^{1,5}

¹Клинички центар Србије, Клиника за дигестивну хирургију – I хируршка клиника, Одељење за минимално инвазивну хирургију горњег дигестивног тракта, Београд, Србија;

²Институт за јавно здравље, Шабац, Србија;

³Универзитет у Приштини, Медицински факултет, Косовска Митровица, Србија;

⁴Универзитет у Београду, Медицински факултет, Институт за медицинску статистику и информатику, Београд, Србија;

⁵Универзитет у Београду, Медицински факултет, Београд, Србија;

⁶Универзитет у Единбургу, Медицински факултет, Единбург, Уједињено Краљевство

САЖЕТАК

Увод/Циљ Недавно објављене студије показале су нарушавање квалитета живота повезаног за здрављем (КЖПЗ) код болесника са дијагностикованом гастроезофагеалном рефлуксном болешћу (ГЕРБ) и функционалном диспепсијом (ФД). Прегледом доступне литературе нисмо нашли студију која се бави поређењем утицаја ове две хроничне незаразне болести на КЖПЗ.

Циљ рада је био да упореди КЖПЗ болесника са дијагностиковом ГЕРБ и ФД.

Метод Студијом су обухваћена 1236 испитаника са дијагностикованом ГЕРБ и ФД. Тренутни узорак је екстраполиран из велике студије пресека која је спроведена у установама примарне здравствене заштите у Србији. ГЕРБ је дијагностикована према Монреалској дефиницији болести за популационе студије. ФД је дијагностикована према Римским III критеријумима. У испитивању је коришћена српска верзија општег упитника за процену КЖПЗ Центра за контро-

лу и превенцију болести у Атланти. Коришћене су методе дескрипционе статистике, као метод скор подударности поређењем варијабли као што су старост, пол, ниво образовања и узимање терапије.

Резултати Поређењем тренутног здравственог стања испитаника, слични резултати су добијени у обе групе. Даљом анализом утврђено је да испитаници са дијагностикованом ФД имају нарушенији КЖПЗ у доменима физичког и менталног здравља и обављању уобичајених активности у односу на испитанике са ГЕРБ.

Закључак Резултатима студије показано је озбиљно нарушавање КЖПЗ у обе групе испитаника, с тим да у неким доменима свакодневног живота испитаници са ФД имају веће нарушавање КЖПЗ у односу на болеснике са дијагностикованом ГЕРБ.

Кључне речи: квалитет живота; гастроезофагеални рефлукс; функционална диспепсија; популациона студија; анкете и упитници